Table 2.
Analysis of interaction between zilovertamab at 25 and 50 µg/mL doses and standard chemotherapy drugs at IC70 doses (as shown in Table 1) in high-grade serous ovarian cancer and endometrial cancer cell lines at 72 h. Survival index (SI) ratio listed in the table indicated synergistic (<0.8), subadditive (>1.2) or additive (0.8–1.2, grey shaded) effect of the drug combination. Data are presented as the mean (lower 95% confidence interval, upper 95% confidence interval).
| Zilovertamab (25 µg/mL) | Zilovertamab (50 µg/mL) | |||||
|---|---|---|---|---|---|---|
| +Cisplatin | +Paclitaxel | +Olaparib | +Cisplatin | +Paclitaxel | +Olaparib | |
| CaOV3 | 1.37 (1.18, 1.56) | 1.47 (1.04, 1.90) | 1.27 (1.10, 1.44) | 1.51 (1.33, 1.69) | 1.37 (0.92, 1.82) | 1.41 (1.18, 1.64) |
| CaOV3CisR | 1.10 (0.74, 1.46) | 1.30 (0.74, 1.86) | 1.01 (0.80, 1.22) | 1.54 (0.00, 4.62) | 1.36 (0.87, 1.85) | 1.42 (0.08, 2.76) |
| PEO1 | 1.56 (0.95, 2.17) | 1.57 (1.00, 2.14) | 1.55 (0.81, 2.29) | 1.74 (1.14, 2.34) | 1.28 (0.84, 1.72) | 1.40 (0.91, 1.88) |
| PEO4 | 1.72 (0.48, 1.96) | 1.35 (0.90, 1.8) | 1.56 (0.82, 2.30) | 1.44 (0.47, 2.41) | 1.28 (0.69, 1.87) | 1.57 (0.26, 2.88) |
| Ishikawa | 1.54 (0.96, 2.12) | 1.63 (0.72, 2.54) | 3.77 (0.45, 7.09) | 2.02 (1.42, 2.62) | 1.84 (0.77, 2.9) | 3.73 (1.08, 6.38) |
| KLE | 1.03 (0.81, 1.25) | 0.99 (0.73, 1.25) | 1.04 (0.64, 1.44) | 1.40 (0.83, 1.97) | 1.15 (0.57, 1.73) | 1.29 (0.58, 2) |